• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The landscape of mA regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance.

作者信息

Zhang Chaoqi, Zhang Zhihui, Zhang Zhen, Luo Yuejun, Wu Peng, Zhang Guochao, Xue Liyan, Zeng Qingpeng, Wang Lide, Yang Zhaoyang, Zeng Hua, Zheng Bo, Tan Fengwei, Xue Qi, Gao Shugeng, Sun Nan, He Jie

机构信息

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.

出版信息

Mol Cancer. 2021 Sep 27;20(1):122. doi: 10.1186/s12943-021-01408-5.

DOI:10.1186/s12943-021-01408-5
PMID:34579719
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8474928/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec25/8474928/61c5f521ca52/12943_2021_1408_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec25/8474928/59f4f715997d/12943_2021_1408_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec25/8474928/61c5f521ca52/12943_2021_1408_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec25/8474928/59f4f715997d/12943_2021_1408_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec25/8474928/61c5f521ca52/12943_2021_1408_Fig2_HTML.jpg

相似文献

1
The landscape of mA regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance.小细胞肺癌中mA调节因子的格局：分子特征、免疫肿瘤学特征及临床相关性。
Mol Cancer. 2021 Sep 27;20(1):122. doi: 10.1186/s12943-021-01408-5.
2
Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape.小细胞肺癌中DNA损伤与修复途径的分析揭示了其在免疫格局中的抑制作用。
Mol Cancer. 2021 Oct 7;20(1):130. doi: 10.1186/s12943-021-01432-5.
3
[The molecular pathogenesis of small cell lung cancer].[小细胞肺癌的分子发病机制]
Zhongguo Fei Ai Za Zhi. 2010 Nov;13(11):C46-57. doi: 10.3779/j.issn.1009-3419.2010.11.18.
4
Identification of a New Prognostic Risk Signature of Clear Cell Renal Cell Carcinoma Based on N-Methyladenosine RNA Methylation Regulators.基于 N6-甲基腺苷 RNA 甲基化调控因子鉴定透明细胞肾细胞癌的新预后风险特征。
J Immunol Res. 2021 Feb 12;2021:6617841. doi: 10.1155/2021/6617841. eCollection 2021.
5
Characterization of mA RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma.mA RNA 甲基化调控因子的特征可预测肺腺癌的生存和免疫治疗反应。
Front Immunol. 2021 Dec 17;12:782551. doi: 10.3389/fimmu.2021.782551. eCollection 2021.
6
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).程序性死亡配体 1（PD-L1）、B7 同源蛋白 3（B7-H3）、B7 同源蛋白 4（B7-H4）和肿瘤浸润淋巴细胞（TILs）在人小细胞肺癌（SCLC）中的表达及临床意义。
J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1.
7
MicroRNA-217 inhibits proliferation and promotes apoptosis of small cell lung cancer cells via targeting PCDH8.微小RNA-217通过靶向原钙黏蛋白8抑制小细胞肺癌细胞的增殖并促进其凋亡。
Panminerva Med. 2021 Mar;63(1):95-96. doi: 10.23736/S0031-0808.19.03674-7. Epub 2019 Jul 8.
8
Lung carcinoma signaling pathways activated by smoking.吸烟激活的肺癌信号通路。
Chin J Cancer. 2011 Aug;30(8):551-8. doi: 10.5732/cjc.011.10059.
9
Evaluation of role of Notch3 signaling pathway in human lung cancer cells.Notch3信号通路在人肺癌细胞中的作用评估。
J Cancer Res Clin Oncol. 2016 May;142(5):981-93. doi: 10.1007/s00432-016-2117-4. Epub 2016 Feb 2.
10
ERCC1 and small cell lung cancer.ERCC1与小细胞肺癌
J Thorac Oncol. 2010 Nov;5(11):1876-7. doi: 10.1097/JTO.0b013e3181f69fb1.

引用本文的文献

1
MrGPS: an m6A-related gene pair signature to predict the prognosis and immunological impact of glioma patients.MrGPS：一种与 m6A 相关的基因对特征，用于预测胶质瘤患者的预后和免疫影响。
Brief Bioinform. 2023 Nov 22;25(1). doi: 10.1093/bib/bbad498.
2
Identification of alternative splicing associated with clinical features: from pan-cancers to genitourinary tumors.与临床特征相关的可变剪接的鉴定：从泛癌到泌尿生殖系统肿瘤
Front Oncol. 2023 Sep 25;13:1249932. doi: 10.3389/fonc.2023.1249932. eCollection 2023.
3
Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities.mA、mC 和 Ψ RNA 修饰在癌症中的作用：新的治疗机会。
Mol Cancer. 2021 Jan 18;20(1):18. doi: 10.1186/s12943-020-01263-w.
3
Small-cell lung cancer.小细胞肺癌。
对与一碳代谢相关基因及其与肺腺癌预后、肿瘤微环境、化疗耐药性和免疫治疗的关联进行综合分析。
Front Mol Biosci. 2022 Nov 11;9:1034208. doi: 10.3389/fmolb.2022.1034208. eCollection 2022.
4
Comprehensive analysis of N6-methyladenosine-related lncRNAs reveals distinct hepatocellular carcinoma subtypes with immunotherapeutic implications.对N6-甲基腺嘌呤相关长链非编码RNA的综合分析揭示了具有免疫治疗意义的不同肝细胞癌亚型。
Am J Transl Res. 2022 Sep 15;14(9):6504-6520. eCollection 2022.
Nat Rev Dis Primers. 2021 Jan 14;7(1):3. doi: 10.1038/s41572-020-00235-0.
4
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease.小细胞肺癌的表观遗传学景观：巨大难治性疾病的小缩影。
Semin Cancer Biol. 2022 Aug;83:57-76. doi: 10.1016/j.semcancer.2020.11.006. Epub 2020 Nov 18.
5
mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.mA 修饰在编码和非编码 RNA 中的作用及其在癌症中的治疗意义。
Cancer Cell. 2020 Mar 16;37(3):270-288. doi: 10.1016/j.ccell.2020.02.004.
6
Immunotherapeutic approaches for small-cell lung cancer.小细胞肺癌的免疫治疗方法。
Nat Rev Clin Oncol. 2020 May;17(5):300-312. doi: 10.1038/s41571-019-0316-z. Epub 2020 Feb 13.
7
Molecular characterization and clinical relevance of mA regulators across 33 cancer types.跨越 33 种癌症类型的 mA 调节剂的分子特征和临床相关性。
Mol Cancer. 2019 Sep 14;18(1):137. doi: 10.1186/s12943-019-1066-3.
8
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.利用 CRISPR-Cas9 筛选技术对癌症治疗靶点进行优先级排序。
Nature. 2019 Apr;568(7753):511-516. doi: 10.1038/s41586-019-1103-9. Epub 2019 Apr 10.